ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.57
0.23%
US Tech 100
19,279.20
-0.67%
S&P 500
5,473.17
-0.25%
US Dollar vs CAD
1.36905
-0.11%
Bitcoin
65,015.88
0.07%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Tango Therapeutics Inc (TNGX) Share Price

Tango Therapeutics Inc

Tango Therapeutics Inc (TNGX)

9.55
0.01
(0.10%)
At close: June 20 3:00PM
Delayed by 15 minutes
9.55
0.00
( 0.00% )
After Hours: 3:17PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
9.55
Bid
7.92
Ask
9.60
Volume
741,430
9.36 Day's Range 9.80
2.88 52 Week Range 13.03
Market Cap
974.002M
Previous Close
9.54
Open
9.69
Last Trade
12
@
9.57
Last Trade Time
15:25:33
Financial Volume
US$ 7,107,146
VWAP
9.5857
Average Volume (3m)
597,291
Shares Outstanding
101,989,696
Dividend Yield
-
PE Ratio
-9.57
Earnings Per Share (EPS)
-1
Revenue
36.53M
Net Profit
-101.74M

About Tango Therapeutics Inc

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.tangotx.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Tango Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TNGX. The last closing price for Tango Therapeutics was US$9.54. Over the last year, Tango Therapeutics shares have traded in a share price range of US$ 2.88 to US$ 13.03.

Tango Therapeutics currently has 101,989,696 shares outstanding. The market capitalization of Tango Therapeutics is US$974 million. Tango Therapeutics has a price to earnings ratio (PE ratio) of -9.57.

TNGX Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

June 07 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 07 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 07 2024
Edgar (US Regulatory)

Form 8-K - Current report

June 06 2024
Edgar (US Regulatory)

Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that...

June 05 2024
Business Wire

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program PR Newswire STOCKHOLM, May 23, 2024 STOCKHOLM, May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq...

May 23 2024
PR Newswire (US)

Form 8-K - Current report

May 23 2024
Edgar (US Regulatory)

Tango Therapeutics Announces Discontinuation of TNG348 Program

– The phase 1/2 clinical trial of TNG348, a USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts – – Cash runway extended into 2027, PRMT5 and CoREST clinical...

May 23 2024
Business Wire
Period †ChangeChange %OpenHighLowAvg. Daily VolVWAP
1226.49006622527.559.87.4412394689.04738678CS
42.8442.32488822656.719.86.467514147.75653504CS
121.8423.86511024647.719.86.465972917.65753185CS
26-0.67-6.5557729941310.2213.0056.466328309.29317964CS
526.04172.079772083.5113.032.8810588498.38724956CS
156-0.06-0.6243496357969.6118.842.475247288.01877964CS
260-0.06-0.6243496357969.6118.842.475247288.01877964CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GRCGold Springs Resource Corp
$ 0.09
(20.00%)
255.2k
SFDNXT Energy Solutions Inc
$ 0.16
(18.52%)
118k
SAMStarcore International Mines Ltd
$ 0.14
(16.67%)
525
DSVDiscovery Silver Corp
$ 1.03
(13.19%)
913.48k
PYRPyroGenesis Canada Inc
$ 0.69
(13.11%)
191.75k
CFXCanfor Pulp Products Inc
$ 1.04
(-25.71%)
141.77k
AEZSAeterna Zentaris Inc
$ 6.04
(-24.50%)
14.45k
LPENLoop Energy Inc
$ 0.025
(-16.67%)
15.04k
ETEvertz Technologies Ltd
$ 13.30
(-13.30%)
120.44k
AABAberdeen International Inc
$ 0.035
(-12.50%)
1.61M
CNQCanadian Natural Resources Ltd
$ 47.87
(1.36%)
29.03M
TRPTC Energy Corporation
$ 52.25
(-0.08%)
14.09M
SUSuncor Energy Inc
$ 50.82
(0.08%)
8.95M
MFCManulife Financial Corporation
$ 35.23
(0.46%)
7.75M
POWPower Corp of Canada
$ 37.57
(-0.71%)
6.65M

TNGX Discussion

View Posts
Monksdream Monksdream 2 months ago
TNGX under $10
👍️0
bikaver bikaver 9 months ago
Stopped out with small loss.
👍️0
bikaver bikaver 10 months ago
TNGX......Holding up well, but will tumble soon.
👍️0
bikaver bikaver 10 months ago
TNGA.....short @ 8.60 This is the strength that I wanted to see!
👍️0
bikaver bikaver 10 months ago
TNGX.....Studying the TNGX chart this evening. I'll short it at a good sign of strength if the opportunity presents itself tomorrow.
👍️0
SmokeSignals SmokeSignals 10 months ago
up $4>H.C. Wainwright Reaffirms Their Buy Rating on Tango Therapeutics (TNGX)AUGUST 8, 2023TIPRANKS
Barclays Releases a Buy Rating on Tango Therapeutics (TNGX)AUGUST 8, 2023TIPRANKS
Goldman Sachs Keeps Their Buy Rating on Tango Therapeutics (TNGX)AUGUST 7, 2023TIPRANKS
Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business HighlightsAUGUST 7, 2023TIPRANKS
Tango Therapeutics reports Q2 EPS (23c), consensus (34c)AUGUST 7, 2023TIPRANKS
👍️0

Your Recent History

NASDAQ
TNGX
Tango Therapeutics
AMEX
YMI
YM Biosciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved